Changes in Renal Function and Body Composition in Pulmonary Hypertension
- Conditions
- Pulmonary HypertensionRenal Function Abnormal
- Interventions
- Diagnostic Test: No intervention
- Registration Number
- NCT03039972
- Lead Sponsor
- University of Giessen
- Brief Summary
Changes in renal function and body composition in patients with pulmonary hypertension
- Detailed Description
This prospective single-center study is designed to analyze changes in renal function and body composition in patients with suspected or pre-diagnosed pulmonary hypertension at pulmonary hypertension outpatient clinic, University Hospital Giessen and Marburg, Campus Giessen.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 500
- Subjects older than 18 years at pulmonary hypertension outpatient clinic
- Subjects who signed informed consent forms
- Patients refusing to participate or withdraw consent during follow-up
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Pulmonary Hypertension No intervention Adult outpatients with suspected or prediagnosed pulmonary hypertension irrespective of subclass and all chronic kidney disease stages
- Primary Outcome Measures
Name Time Method Changes in renal function in patients with pulmonary hypertension 1 year Estimated GFR based on Chronic Kidney Disease Epidemiology Collaboration-creatinine-cystatin C will be used to determine renal function at baseline and at 1 year follow-up
- Secondary Outcome Measures
Name Time Method Changes in nutritional status in patients with pulmonary hypertension 1 year Bioimpedance analysis will be used to determine lean tissue and fat mass at baseline and at 1 year follow-up
Changes in hydration status in patients with pulmonary hypertension 1 year Bioimpedance analysis will be used to determine hydration status at baseline and at 1 year follow-up
Prognostic value of baseline renal function, hydration and nutritional status on pulmonary hypertension-associated morbidity and mortality 1 year pulmonary hypertension-associated morbidity and mortality (defined as escalation of pulmonary hypertension-specific therapy, unscheduled hospitalization and all-cause mortality) will be prospectively assessed during follow-up period
Trial Locations
- Locations (1)
University Clinic Giessen and Marburg - Campus Giessen
🇩🇪Giessen, Hessen, Germany